Onglyza improves blood-sugar control in patients with high cardiovascular disease risk
PRINCETON, N.J. — A drug made by Bristol-Myers Squibb and AstraZeneca improved several measures of blood-sugar control in Type 2 diabetes patients at high risk of cardiovascular disease, according to results of a late-stage clinical trial announced Monday.
The drug makers announced results of a 1,681-patient phase-3 trial of Onglyza (saxagliptin), in which patients received 5-mg doses of the drug. Results of the 24-week trial showed improved blood-sugar control as measured by HbA1C, fasting plasma glucose and post-meal glucose compared with placebo. Results of the study were presented Monday at the 17th World Congress on Heart Disease in Toronto.
"The population of patients with Type 2 diabetes who are at increased risk for cardiovascular disease was highlighted in a recently issued position statement by the American Diabetes Association and the European Association for the Study of Diabetes," lead study investigator and AstraZeneca global medical affairs manager William Cook said.
The drug, combined with exercise and changes in diet, is already approved for various patients with Type 2 diabetes.
Randy Heiser joins McKesson as director of retail national accounts of Six Sigma
SAN FRANCISCO — Randy Heiser recently joined McKesson as director of retail national accounts of Six Sigma, DSN has learned.
Heiser comes to McKesson from Giant Eagle, where he was VP pharmacy and oversaw the day-to-day operation of more than 209 locations. Heiser started his retail pharmacy career in 1980 with Rite Aid, where he worked his way up to director of professional placement and director of pharmacy and therapeutic
Heiser graduated with a bachelor of science degree in pharmacy from the University of Pittsburgh in 1983, and went on to receive his MBA from the University of Pittsburgh in 1999.
TIGI names champion gymnast Nastia Liukin brand spokeswoman
LEWISVILLE, Texas — TIGI Haircare — whose brands include Bed Head, Catwalk, Rockaholic and TIGI Cosmetics — has tapped gymnastic medalist Nastia Liukin to be its newest spokeswoman.
TIGI will embark on a multiyear deal with Liukin, involving her in many facets of the brand, including campaign advertising, social media, consumer promotions and appearances, as well as a co-branded product line.
“At TIGI, our business is built on our dedication to hairdressing, but we thrive on being different, and our culture is disruptive and progressive. We develop and specialize in products and tools that encourage creativity, expression and individuality —traits that Nastia Liukin embodies. It’s rare that you find a spokesmodel or partner for your brand that truly believes in your products. Her undeniable beauty, style and passion for life make her a perfect personality for our brands,” stated Vince Davis, general manager for TIGI North America. “TIGI looks forward to our partnership with Nastia.”
Born in Russia, Liukin began her gymnastic career at the age of 6 years old. As the daughter of two gymnasts who each earned world champion titles in their careers and who became gymnastics coaches themselves, it was only natural that Liukin found herself in the gym from a very young age. She was an elite gymnast by the time she was 12 years old. Specializing in the vault and balance beam, Liukin joined the ranks of Mary Lou Retton and Shannon Miller as the only American gymnast to win five medals in the 2008 Beijing games.
Beyond the chalk, Liukin has a passion for acting and modeling. In addition to television and radio interviews, she has also been featured in a number of international and national advertising campaigns. She made a cameo appearance on the television show “Gossip Girl,” as well as a small role in the gymnastics-themed movie “Stick It.”